Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Oct;64(10):2085-2089.
doi: 10.1007/s00234-022-03010-y. Epub 2022 Jul 9.

Cytotoxic lesions of the corpus callosum after COVID-19 vaccination

Hiroya Ohara  1   2 , Hironori Shimizu  1   2 , Takehito Kasamatsu  3 , Akihiro Kajita  3 , Kenji Uno  3 , Khin Wee Lai  4 , Balachandar Vellingiri  5 , Kazuma Sugie  2 , Masako Kinoshita  6   7
Affiliations
Case Reports

Cytotoxic lesions of the corpus callosum after COVID-19 vaccination

Hiroya Ohara et al. Neuroradiology. 2022 Oct.

Abstract

A 23-year-old previously healthy man (Patient 1) and a 33-year-old woman with a past history of depression (Patient 2) developed neurological symptoms approximately 1 week after receipt of the first COVID-19 mRNA vaccination and deteriorated over the next week. Patient 1 reported nausea, headache, a high fever, and retrograde amnesia. Patient 2 reported visual disturbance, headache, dysarthria, a left forearm tremor, dysesthesia of the mouth and distal limbs, and visual agnosia. PCR test results for SARS-CoV-2 were negative. Complete blood cell count, biochemistry, and antibody test and cerebrospinal fluid test findings were unremarkable. Diffusion-weighted and fluid-attenuated inversion recovery MRI of the brain showed a high signal intensity lesion at the midline of the splenium of the corpus callosum compatible with cytotoxic lesions of the corpus callosum (CLOCCs). High-dose intravenous methylprednisolone improved their symptoms and imaging findings. CLOCCs should be considered in patients with neurological manifestation after COVID-19 vaccination.

Keywords: COVID-19; COVID-19 mRNA vaccine; Coronavirus disease 2019; Cytotoxic lesions of the corpus callosum; Mild encephalitis/encephalopathy with reversible splenial lesion.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Magnetic resonance images of the brain of Patient 1 on Day 18 (A) and on Day 25 (B) after COVID-19 vaccination. A Diffusion-weighted image (DWI) (left) shows restricted diffusion in the splenium with low apparent diffusion coefficient (ADC) values (middle), and fluid-attenuated inversion recovery image (FLAIR) (right) shows a high signal intensity lesion at the midline of the splenium of the corpus callosum (arrows). B The lesion disappeared after intravenous high-dose methylprednisolone therapy
Fig. 2
Fig. 2
Magnetic resonance images of the brain of Patient 2 on Day 17 (A) and on Day 29 (B) after COVID-19 vaccination. A Diffusion-weighted image (DWI) (left) shows restricted diffusion in the splenium with low apparent diffusion coefficient (ADC) values (middle), and fluid-attenuated inversion recovery image (FLAIR) (right) shows a high signal intensity lesion at the midline of the splenium of the corpus callosum (arrows). B The lesion disappeared after intravenous high-dose methylprednisolone therapy
See this image and copyright information in PMC

Comment in

References

    1. Kadali RAK, Janagama R, Peruru S, et al. Non-life-threatening adverse effects with COVID-19 mRNA-1273 vaccine: a randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms. J Med Virol. 2021;93:4420–4429. doi: 10.1002/jmv.26996. - DOI - PMC - PubMed
    1. Kadali RAK, Janagama R, Peruru S, Malayala SV. Side effects of BNT162b2 mRNA COVID-19 vaccine: a randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. Int J Infect Dis. 2021;106:376–381. doi: 10.1016/j.ijid.2021.04.047. - DOI - PMC - PubMed
    1. Starkey J, Kobayashi N, Numaguchi Y, Moritani T. Cytotoxic lesions of the corpus callosum that show restricted diffusion: mechanisms, causes, and manifestations. Radiographics. 2017;37:562–576. doi: 10.1148/rg.2017160085. - DOI - PubMed
    1. Kim SS, Chang KH, Kim ST, et al. Focal lesion in the splenium of the corpus callosum in epileptic patients: antiepileptic drug toxicity? AJNR Am J Neuroradiol. 1999;20:125–129. - PubMed
    1. Tada H, Takanashi J, Barkovich AJ, et al. Clinically mild encephalitis/encephalopathy with a reversible splenial lesion. Neurology. 2004;63:1854–1858. doi: 10.1212/01.wnl.0000144274.12174.cb. - DOI - PubMed

Publication types